At a glance
ClinicalIndex Comparison RecordN/ACompleted· 84 enrolled
Drug / intervention
stereotactic body radiotherapyradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer
In Brief
A clinical study evaluating stereotactic body radiotherapy for Prostate Cancer. Completed, enrolled 84 participants across 1 site.
Detailed Summary
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of organ confined prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJun 2011
Primary CompletionApr 2019
TodayJul 2026
First PostedMay 12, 2011
Enrollment StartJun 1, 2011
Primary CompletionApr 1, 2019
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 15.1 years ago
Interventions
stereotactic body radiotherapyradiation
Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.